Dr. Pollet has a PhD degree in Biochemistry and brings over 25 years of experience in the diagnostics and biotechnology industries. He led Multiplicom NV, a European diagnostics company with state-of-the-art genetic testing technology and products, before this was acquired by Agilent Technologies. Before that, Dr. Pollet served as Chief Business Officer and Board Member at Cellectis SA, as well as in several other senior leading positions for other companies (click for full bio).

In the pre-incorporation phase, Dr. Pollet will be available for consultation with our research groups. Dr. Pollet and the other Entrepreneurs in Residence will provide regular coaching sessions and mentoring support to portfolio companies.

About the Oncode Oncology Bridge Fund
Oncode BV createdthe Oncode Oncology Bridge Fund (Bridge Fund) as part of its overall valorization strategy. Its objective is providing early stage capital to support the creation and growth of new enterprises based on excellent science performed by Oncode Researchers and accelerate the translation of innovative cancer research into products and services that benefit patients. The Bridge Fund stands to make a significant impact on the lives of cancer patients. By facilitating the development of new treatment options and diagnostic methods, the Bridge Fund will contribute to improving treatment outcomes for cancer patients all over the world. Please contact Shobhit Dhawan via [email protected] if you’d like to know more about the Bridge Fund.